Richard Shea

Rich Shea is a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as CEO of Basking Biosciences since 2019, Rich Shea leads efforts to develop innovative thrombolytic drugs while also holding a board position at Glycan Therapeutics, which focuses on glycomics and sulfated carbohydrate synthesis. Previously, Rich Shea was CEO of Rediscovery Life Sciences AKI LLC and Vascular Pharmaceuticals, where initiatives included repositioning compounds and overseeing the development of monoclonal antibodies for diabetic nephropathy. Additional leadership roles include board member positions at CED and Fertility Focus, LTD, strategic advisor at Dignify Therapeutics, and vice president of Women's Health at Norgenix, among others. Rich Shea holds an MBA from Duke University and a B.S. from the University of Notre Dame.